Evidence map›Paper›PMID 39196719›Full record

ArticleUrology practice2024

Associations Between Prostate Magnetic Resonance Imaging, Genomic Testing, and Treatment for Localized Prostate Cancer.

Vinaik M Sundaresan, Rong Wang, Jessica B Long, Preston C Sprenkle, Tyler M Seibert, Stacy Loeb, Matthew R Cooperberg, William J Catalona, Xiaomei Ma, Cary P Gross and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Urology practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Vinaik M SundaresanDepartment of Urology, Yale School of Medicine, New Haven, Connecticut.ORCID 0000-0001-6150-3793
Rong WangYale Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, New Haven, Connecticut.
Jessica B LongYale Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, New Haven, Connecticut.
Preston C SprenkleDepartment of Urology, Yale School of Medicine, New Haven, Connecticut.
Tyler M SeibertDepartment of Radiation Medicine and Applied Sciences, University of California, San Diego, La Jolla, California.
Stacy LoebDepartments of Urology and Population Health, New York University Langone Health, New York, New York.
Matthew R CooperbergDepartment of Urology, University of California, San Francisco, San Francisco, California.
William J CatalonaDepartment of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Xiaomei MaYale Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, New Haven, Connecticut.
Cary P GrossYale Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, New Haven, Connecticut.
Michael S LeapmanDepartment of Urology, Yale School of Medicine, New Haven, Connecticut.

Funding

Targeting FOXA1-downstream pathways: a novel therapeutic strategy for castration-resistant prostate cancerP50CA180995 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI ABDULKADIR, SARKI A. · 2015 to 2025
$19.9M
Short Term Research Training: Students in Health Professional SchoolsT35DK104689 · NIDDK · YALE UNIVERSITY · PI LLOYD G CANTLEY, Sarwat I Chaudhry · 2015 to 2026
$2.6M
Understanding the Adoption and Impact of New Risk Assessment Technologies in Prostate Cancer CareK08CA237872 · NCI · YALE UNIVERSITY · PI LEAPMAN, MICHAEL STUART · 2019 to 2023
$1.1M
Mechanistic Dissection of an Arginine Methyltransferase Dependency in CancerK08CA204732 · NCI · YALE UNIVERSITY · PI WILSON, FREDERICK H · 2017 to 2021
$876k
CDC HHS NU58DP007156NCI NIH HHS K08 CA204732NCI NIH HHS K08 CA237872NCI NIH HHS P50 CA180995NIDDK NIH HHS T35 DK104689
6 · The paper itself

Abstract

introductionAlthough prostate MRI and tissue-based gene expression (genomic) tests improve staging and estimates of prostate cancer prognosis, their association with the intensity of treatment patients receive is not well understood.

methodsWe performed a retrospective cohort study of Medicare beneficiaries diagnosed with clinically localized prostate cancer in 2013 through 2017 in the Surveillance, Epidemiology, and End Results database. The primary study outcome was the receipt of treatment intensification in the first 12 months after diagnosis (defined as the addition of androgen deprivation therapy among patients receiving radiation or pelvic lymphadenectomy among those undergoing radical prostatectomy). We assessed associations between the receipt of prostate MRI and genomic testing and treatment intensification, adjusting for clinical and sociodemographic factors and further stratifying the analyses by risk status.

resultsWe identified 37,064 patients with clinically localized prostate cancer, including 6398, 22,011, and 5976 with low, intermediate, and high D'Amico-risk disease, respectively. Among all treated patients, receipt of prostate MRI was associated with increased odds of treatment intensification (odds ratio 1.76, 95% CI 1.65-1.88,

conclusionsProstate MRI was associated with intensified treatment across risk strata, while genomic testing was associated with lower intensity of treatment among high-risk disease. Additional study is needed to determine whether use of imaging and risk stratification tools leads to improved long-term patient outcomes.

Indexed as

Magnetic Resonance ImagingProstatic NeoplasmsAgedAged, 80 and overCohort StudiesGenetic TestingGenomicsHumansMaleRetrospective Studiesactive surveillanceprostate biopsyprostate cancerPSA

Identifiers

PMID39196719
PMCPMC12400587

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.